Smart Discharges for Mom & Baby

Smart Discharges for Mom & Baby: Saving Mother-newborn Dyads by Developing a Predictive Risk Model to Identify Vulnerable Dyads and Guide Delivery of Evidence-based, Locally-informed Interventions for Targeted Post-discharge Care

This study aims to build a predictive algorithm that identifies mother-newborn dyads most at risk of death or complications in the 6 weeks after birth. The investigators will conduct a multi-site cohort study with 7,000 dyads in Uganda and engage with local stakeholders (e.g., patients, healthcare workers, and health policy-makers) to develop an evidence-based bundle of interventions that address key practice gaps and the critical factors leading to death and complications in these dyads. In the investigator's epidemiological study of post-delivery post-discharge outcomes in 3,236 dyads in Uganda (2017-2020), results indicated that most newborn and maternal readmissions were due to infectious illness (i.e. sepsis, surgical site infections, malaria), and primarily occurred early in the post-discharge period. Thus, the focus of this study will be identifying interventions that target these common and early outcomes, for both mothers and newborns, using World Health Organization recommendations, patient and caregiver experiences, and stakeholder recommendations. If successful, results will inform the next steps of this project, which is the external validation of the model and clinical evaluation of a personalized approach to improving health outcomes and health-seeking behaviour for mothers and newborns.

Study Overview

• Status: Completed
• Conditions: Neonatal Sepsis; Maternal Sepsis
• Intervention / Treatment: Other: Observational only

Detailed Description

PURPOSE

Neonatal outcomes are highly correlated with the health of the mother, an example of this is shown repeatedly by poor rates of survival of infants after maternal death. Prediction of risk, based on the mother and infant as a pair, is a major gap in current research and yet vital to the survival of both the mom and the infant. Thus, maternal and child health outcomes can be improved by identifying both mothers and babies at increased risk of mortality or serious morbidity after hospital discharge and allocating scarce resources for targeted follow-up to those most vulnerable. This allows the investigators to not only improve health outcomes but benefits the health system with efficient use of resources.

JUSTIFICATION

Since 2011, the investigators have been working with partners in Uganda to develop, validate, and implement an innovative program for children under 5 years who have been discharged following hospitalization for suspected sepsis. In this research and implementation program, called Smart Discharges, healthcare workers use an individualized risk prediction score to identify children at high risk of death or complications after discharge from a hospital following treatment for suspected sepsis. They can then use this score to guide the intensity of a counselling and community-referral program. While all participants receive counselling, only those above a certain risk threshold receive down-referrals to community health facilities. The investigators have shown that this approach may reduce post-discharge child mortality after in-hospital treatment for suspected sepsis by as much as 30%. Now, the investigators are working to expand their innovative precision public health approach to improving post-discharge care for mother-newborn dyads.

Findings will inform the development an evidence-based bundle of care for both the mother and newborn. This package will ensure that low-risk mother-infant pairs receive less burdensome (yet pragmatic and feasible) postpartum care, while high risk pairs receive a more extensive bundle of interventions (such as education, nutrition, healthcare interaction and community support). The Smart Discharges for Mom & Baby package will include support targeting aspects of both clinical and emotional wellbeing. Additional extensions of this work will include validating the risk models in women who deliver at home or suffer a stillbirth to ensure that more women and babies can benefit from the proposed intervention.

HYPOTHESIS

Maternal and infant characteristics collected at the time of discharge following a facility delivery can predict the risk of maternal or neonatal death or need for re-admission within six weeks of birth.

OBJECTIVE

The primary objective is to inform the development of an integrated maternal and newborn risk-based post-discharge care program. Specifically, the study aims to (1) develop and internally validate clinical risk prediction models for identifying dyads at high-risk of death or hospital readmission in the 6-week post-delivery post-discharge period, and (2) identify gaps and opportunities during in-hospital, discharge, and post-discharge care to inform the future development of an evidence-and risk-based bundle of interventions to improve postnatal care (PNC) for dyads.

DESIGN

This is a mixed-methods study using both quantitative and qualitative techniques to explore and map the current postnatal discharge processes in Uganda using data from two distinct hospital settings.

• Phase I) The team will conduct an observational cohort study informed through direct observation of the mother and newborn dyad prior to facility discharge and after delivery and follow-up telephone interviews conducted at six-weeks post-discharge.
• Phase II) The team will conduct journey mapping with a subset of dyads enrolled in the observational cohort using direct observation and follow-up telephone interviews.
• Phase III) The team will conduct a process mapping exercise using focus group discussion methodology with select facility staff.
• Phase IV) The team will conduct focus group discussions with a subset of mothers enrolled in the observational cohort, as well as their family members.

STATISTICAL ANALYSIS

Quantitative analysis: The investigators will summarize all risk factors for mothers and newborns that do and do not experience poor outcomes and estimate univariate associations. For newborns, data will be reported by sex. Derivation of prediction models will be based on optimization of the area under the receiver operating curve (AUROC) and specificity across a variety of modeling and variable selection approaches (e.g., logistic regression, elastic net, support vector machines). Model performance will be based on appropriate re-sampling techniques for internal validation (e.g., cross-validation, bootstrapping). Focus will be on developing parsimonious predictive models (e.g., 5-10 predictor variables) with high sensitivity (>80%). AUROC, sensitivity, and specificity will be reported for each model, along with positive and negative predictive values. Site specific metrics will be compared to ensure consistency across settings, and re-calibration may be considered if individual site performance is lower than expected. Finally, the investigators will assess combined sensitivity and specificity when each individual model is applied to the dyad. Outside of prediction modelling, the sample size will allow the investigators to detect an odds ratio of at least 1.30 for a given risk factor with 80% power and 5% significance and relative precision of 25%. Statistical analysis of quantitative data from journey mapping observation surveys and patient interviews will be performed using R Statistical software to obtain descriptive statistics of the frequency and distribution of each variable.

Qualitative Analysis: the investigators will analyze data collected descriptively and report summary statistics. A diagram of the discharge process will be developed, identifying key areas for improvement during the peri-discharge and post-discharge process. Focus group discussion data will be analyzed using a framework method, which allows themes to be developed inductively from participants and deductively from existing literature. Through an iterative process, transcripts will be coded and analyzed for descriptive and interpretive themes using NVivo. Descriptive themes include barriers to care and post-discharge health-seeking behaviour, while interpretive themes focus on caregiver perspectives of maternal and neonatal death and the role of the health system. The investigators will generate frequencies to describe reported medical symptoms, health-seeking behaviour, and barriers to care, and summarize common themes. Member checking will be used to improve the validity of the results, creating a summary document of the main findings that will be reviewed by health workers who participated in the focus groups. Feedback from patients and families will be obtained over telephone with research nurses who will explain the main findings verbally.

• Study Type: Observational
• Enrollment (Actual): 7182

Contacts and Locations

Study Locations

• Canada
  • British Columbia
    • Vancouver, British Columbia, Canada, V5Z 2X8
      • BC Children's Hospital Research Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

The study population represents women living within the catchments of two study hospitals (Mbarara Regional Referral Hospital and Jinja Regional Referral Hospital) in Uganda, who present for delivery.

Description

Inclusion Criteria:

• Women and adolescent girls aged 12 and above delivering a single or multiple babies at the study hospital during the active recruitment phase.

Exclusion Criteria:

• Inability, for whatever reason, to provide informed consent.
• Language barrier
• Mother is from a refugee camp
• Mother has no access to phone or other means for follow-up
• Mother lives outside of hospital catchment area

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
mother and newborn dyads; We will recruit 6700 mother and newborn dyads from the two participating hospitals. We will continue to follow-up with all patients enrolled in the study until 6 weeks (42 days) post delivery.	Other: Observational only; This is a non-interventional study

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Post-discharge Readmission or Mortality	Composite rate of maternal or neonatal death or re-admission within 6 weeks following delivery	6 weeks following delivery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Post-natal Care Visits	% patients who reported attending at least one post-natal care visits within 6 weeks following delivery	6 weeks following delivery
Post-discharge Health Seeking	% of patients who reported seeking post-discharge care within 6 weeks following delivery	6 weeks following delivery

Collaborators and Investigators

• Sponsor: University of British Columbia
• Investigators: Principal Investigator: Matthew O Wiens, PharmD, PhD, University of British Columbia

Study record dates

Study Major Dates

• Study Start (Actual): April 14, 2022
• Primary Completion (Actual): August 31, 2023
• Study Completion (Actual): April 30, 2024

Study Registration Dates

• First Submitted: December 9, 2022
• First Submitted That Met QC Criteria: February 14, 2023
• First Posted (Actual): February 15, 2023

Study Record Updates

• Last Update Posted (Actual): April 10, 2025
• Last Update Submitted That Met QC Criteria: March 25, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Keywords: maternal health; patient discharge; neonatal health; post-natal care
• Additional Relevant MeSH Terms: Urogenital Diseases; Pathologic Processes; Female Urogenital Diseases and Pregnancy Complications; Pregnancy Complications; Infections; Systemic Inflammatory Response Syndrome; Inflammation; Infant, Newborn, Diseases; Neonatal Sepsis; Sepsis; Toxemia; Pregnancy Complications, Infectious
• Other Study ID Numbers: H21-03709

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: After the study period, a de-identified copy of the data will be prepared for deposition in a repository with open access with proper governance mechanisms. We will make every effort to prevent re-identification of subjects by coding data that has the potential of being identifiable. For example, we will convert all dates into meaningful decimal numbers (date of birth into days since birth and date of recruitment will be reduced to month of recruitment) and all locations will be coded into data that is useful but not specific (such as address converted to distance and direction from facility). We will ensure that data elements with small numbers of subjects (less than 10) will be coded or lumped to avoid identification. The de-identified study data will be made available using a data hosting service (e.g., Dataverse, Vivli, etc.)
• IPD Sharing Time Frame: Data will be deposited to an open access repository with moderated access within 2 years of study completion
• IPD Sharing Access Criteria: Moderated access on a case-by-case basis.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No